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through an association with PIR-B
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The Nogo receptor and paired immunoglobulin-like receptor B (PIR-B) are receptors for three myelin-derived axon-growth
inhibitors, including myelin-associated glycoprotein (MAG). In this study, we report that the p75 receptor is required for the
signal transduction of PIR-B, which interacted with p75 upon ligand binding. In addition, p75 was required for activation of Src
homology2-containingproteintyrosinephosphatase(SHP),whichisinducedbyMAGbindingtoPIR-B.Micecarryingamutation
inthep75geneshowedpromotionofaxonalregenerationafteropticnerveinjury.Thus,ourresultsindicatethatp75hasacritical
role in axon growth inhibition in speciﬁc neuronal tracts.
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Axons in the adult mammalian central nervous system (CNS)
have very limited ability to regenerate after injury.
1 Three
myelin-associated,structurallydistinctproteins—MAG,Nogo,
and oligodendrocyte myelin glycoprotein (OMgp)—are con-
sidered to be involved in this inhibition of axonal regeneration.
These three proteins all bind to the Nogo receptor (NgR) and
PIR-B. For signal transduction mediated by NgR, which has
nointracellular domain,p75 associateswith NgR totransduce
the signal inside the cells,
1 acting as a displacement factor
that releases RhoA from Rho GDP-dissociation inhibitor.
2
This activation of RhoA has a key role in inducing inhibition of
axon growth. In contrast, PIR-B is known to be a receptor for
MHC class I and functions as an inhibitory receptor in B cells
and myeloid cells.
3 The immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) of PIR-B recruit SHP-1 and SHP-2,
which, in turn, modulate immune responses. In neurons, PIR-
B associates with and inactivates tropomyosin-receptor
kinase (Trk) neurotrophin receptors through SHP-1/2.
4
Although this reaction is responsible for axon growth inhibi-
tion, the precise mechanism of signal transduction mediated
by PIR-B remained to be determined.
p75 is a receptor for neurotrophins and modulates the
function of Trk receptors.
5 In some cases, p75 opposes the
function of Trk receptors and induces cell death; in other
cases, it promotes the function of Trk receptors.
6 These
ﬁndingspromptedustohypothesize thatp75is involved inthe
PIR-B-mediated inhibition of Trk receptors.
Results
p75 interacts with PIR-B upon ligand binding in
neurons. We ﬁrst assessed the possible involvement of p75
in the PIR-B signal transduction pathway by performing co-
immunoprecipitation experiments in COS-7 cells transfected
with plasmids encoding carboxy-terminal hemagglutinin (HA)-
tagged full-length p75 (p75 FL-HA) and/or full-length PIR-B
(PIR-B FL). Immunoprecipitation was performed using anti-
PIR-B or anti-HA antibodies. Of the PIR-B immunoprecipitates,
p75 FL-HA was only detected in the p75 FL-HA/PIR-B FL
co-transfected cells (Figure 1a). A complementary experiment
revealed that PIR-B was also co-immunoprecipitated when an
anti-HA antibody was used to immunoprecipitate p75-HA
(Figure 1b), providing evidence that p75 associates with PIR-B
in transfected COS-7 cells.
Co-immunoprecipitation experiments were then used to
identify the molecular determinants of the p75–PIR-B inter-
action. COS-7 cells were transfected with the PIR-B FL
construct, and/or with a construct containing the HA-tagged
transmembrane domain and extracellular domain of p75 (p75
ECDþTM-HA). Exogenous p75 ECDþTM-HA was found to
co-immunoprecipitate with PIR-B FL when immunoprecipita-
tion was performed with both anti-PIR-B antibodies
(Figure 1c) and anti-HA antibodies (Figure 1d). COS-7 cells
were then transfected with constructs coding for an
HA-tagged p75 intracellular domain (p75-ICD-HA) and/or
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www.nature.com/cddisMyc-tagged PIR-B ICD (PIR-B ICD-Myc). The interactions
between these ectopically expressed proteins were then
examined (Figure 1e), and it was found that the exogenous
p75 and PIR-B proteins interact via the intracellular domains,
as well as the extracellular domains.
The ligand-dependent interaction of endogenous p75 and
PIR-B proteins was also examined in postnatal (day 7)
cerebellar granule neurons (CGNs). The CGNs were treated
with or without MAG-Fc, Nogo-Fc, or OMgp for 15min, and
the cell lysates immunoprecipitated with PIR-A/B antibody. It
was found that the interaction of p75 with PIR-B was
enhanced following ligand stimulation (Figure 1f), suggesting
that ligand binding to PIR-B promoted the interaction of
endogenous PIR-B with p75 in the CGNs.
p75 associates with PIR-B/TrkB. As PIR-B associates with
Trk receptors to mediate axon growth inhibition,
4 we
hypothesized that p75 may also be involved in this
signaling complex. The observation that p75 is co-localized
with PIR-B and TrkB in immunostained CGNs supports this
theory (Figure 2a). In order to further test whether this is
the case, we again performed co-immunoprecipitation. To
this end, COS-7 cells were co-transfected with constructs for
HA-tagged full-length TrkB (TrkB FL-HA), PIR-B FL, and p75
FL-Myc, and the cell lysates were immunoprecipitated with
anti-HA, anti-Myc, or anti-PIR-A/B antibodies. Each
co-immunoprecipitation experiment detected interactions
between TrkB FL-HA, p75 FL-Myc, and PIR-B (Figure 2b).
Consistent results were obtained when TrkA was
investigated (Figure 2c). The ligand dependency of these
interactions was then assessed in CGNs expressing all of
these proteins endogenously. The CGNs were treated with or
without MAG-Fc or OMgp for 15min and immunoprecipitated
with anti-TrkB, anti-p75, or anti-PIR-B antibodies. TrkB, p75,
and PIR-B were again found to interact following both MAG-
Fc treatment (Figure 2d, left) and OMgp treatment
(Figure 2d, right), supporting the hypothesis that p75
interacts with TrkB and PIR-B upon ligand binding with
PIR-B.
We subsequently assessed the requirement of p75 for the
associationbetweenTrkBandPIR-Bbyexaminingtheligand-
dependent interaction between TrkB and PIR-B in CGNs in
mice carrying a mutation in the p75 gene.
7 The ligand-
dependent interaction was found to be the same in wild-type
(WT) mice and in mice carrying a mutation in the p75 gene
(Figure 2e). This is consistent with the results obtained from
transfected COS-7 cells (Figure 2b), suggesting that p75 is
involved in the PIR-B/Trk receptor complex, but it may not be
necessary for the interaction between PIR-B and TrkB.
We also examined whether the kinase activity of TrkB is
required for its association with PIR-B. It has previously been
reported that Tyr-705/706 of TrkB is phosphorylated upon
ligand binding, and that phosphorylation of the Tyr-515
of TrkB is required for interactions with adapter proteins.
5
In our experiments, although PIR-B was co-immuno-
precipitated with wild-type TrkB, the level of co-immunopre-
cipitation with TrkB mutated at Tyr-515 or Tyr-705/706
was signiﬁcantly reduced (Figure 2f), providing evidence that
the kinase activity of TrkB is required for the interaction
between TrkB and PIR-B.
p75 is required for MAG functions in neurons. We next
examined whether p75 is required for the effects mediated by
MAG in neurons. Although MAG inhibits neurite growth
in vitro, this effect is dependent on MAG binding to both NgR
and PIR-B. To separate the PIR-B signal from the NgR
signal, we focused on the recent ﬁnding that MAG stimulation
induces dephosphorylation of Trk receptors, which is
required for PIR-B-mediated axon growth inhibition.
4 We
therefore transfected PIR-B, HA-TrkB, and/or p75-Myc
constructs into COS-7 cells, which, as assessed by
immunoblot analysis, do not express detectable levels of
endogenous PIR-B, TrkB, or p75 (data not shown). These
cells were treated with MAG-Fc for 30min, and the TrkB
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Figure 1 p75 interacts with PIR-B. (a and b) Co-immunoprecipitation assays to assess the interaction of PIR-B with p75 in COS-7 cells transiently transfected with the
indicated plasmids. Lysates were immunoprecipitated with anti-PIR-B (a) or anti-HA (b) antibodies, and western blotting was carried out with the indicated antibodies.
Co-immunoprecipitationassayswerealsousedtoexamineinteractionsbetweenthefollowingexogenouslyexpressedproteinsintransfectedCOS-7cells:(candd)full-length
PIR-B with HA-tagged p75 ECD þ TM, and (e) HA-tagged p75 ICD with Myc-tagged PIR-B ICD. (f) Co-immunoprecipitation assay demonstrating the interaction of
endogenous PIR-B with p75 in unstimulated CGNs or CGNs stimulated with MAG-Fc (25mg/ml), Nogo-Fc (200nM), or OMgp (2mg/ml) for 30min. Cell lysates were
immunoprecipitated with an anti-PIR-A/B antibody, and western blots were performed with an anti-p75 antibody. (a–f) are representative images from three to four
independent experiments. IP, immunoprecipitation
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2
Cell Death and Diseasereceptors were immunoprecipitated. Their phosphorylation
status was then examined using western blotting for
phosphotyrosine. It was found that MAG-Fc induced TrkB
dephosphorylation in COS-7 cells co-expressing com-
binations of PIR-B, HA-TrkB, and p75, but not in cells that
did not express p75 (Figure 3a). This requirement for p75 in
MAG-Fc functions was conﬁrmed using dissociated retinal
neurons isolated from mice carrying a mutation in the p75
gene. These experiments showed that although TrkB is
tyrosine dephosphorylated in response to MAG-Fc treatment
in WT-dissociated retinal neurons, there was no change in
TrkB phosphorylation in the neurons isolated from mice
bearing the p75 mutation (Figure 3b). Thus, p75 is required
for MAG-induced tyrosine dephosphorylation of TrkB
receptors. Furthermore, as COS-7 cells co-expressing
combinations of PIR-B, HA-TrkB, and the p75 extracellular
domain did not exhibit TrkB dephosphorylation upon MAG
stimulation, it suggests that the ICD of p75 is required for
MAG-induced tyrosine dephosphorylation of TrkB (ECD;
Figure 3c).
MAG binding to PIR-B has previously been shown in both
CGNs and retinal neurons, to downregulate basal and
neurotrophin-regulated Trk activity through the actions of
SHP-1/2.
4 We therefore attempted to further delineate the
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Figure 2 Interactions between PIR-B, TrkB, and p75 in CGNs. (a) CGNs immunostained for p75 (green), PIR-B (red), and TrkB (blue). Scale Bar: 10mm. (b and c)
Co-immunoprecipitation of the Trk receptors, p75, and PIR-B in COS-7 cells co-expressing combinations of PIR-B FL, and/or p75 FL-Myc with (b) TrkB FL-HA or (c) TrkA
FL-HA. Lysates were immunoprecipitated with the indicated antibodies, followed by western blotting. IP, immunoprecipitation; WB, western blot. (d) Co-immunoprecipitation
assay of CGNs treated with or without MAG-Fc or OMgp for 15min. Lysates were immunoprecipitated with the indicated antibodies, and western blotting was carried out.
(e) Co-immunoprecipitation of TrkB and PIR-B from CGNs obtained from WT and p75-deﬁcient mice (p75 KO). CGNs were treated with or without MAG-Fc for 15min.
(f) Co-immunoprecipitation of exogenously expressed TrkB-HA and p75 FL-Myc with PIR-B FL from COS-7 cells. The TrkB-HA expression vectors used were WT TrkB, or
TrkBwith mutationsat Tyr-515 (Tyr-515F), Tyr-705/706 (Tyr-705/706F),or both (Tyr-515/705/706F). Lysates were immunoprecipitated with anti-PIR-A/Bantibodies, followed
by western blotting with the indicated antibodies
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Cell Death and Diseasemechanism of TrkB dephosphorylation in response to MAG
stimulation. It was found that the transfection of catalytically
inactive SHP-2 (SHP-2 C459S) abrogated MAG-induced
TrkB dephosphorylation (Figure 3d), suggesting that SHP-2
activityisrequiredforthedephosphorylationofTrkB.Because
the expression levels of SHP-1 and SHP-2 were not
signiﬁcantly different between CGNs from WT mice and those
from mice carrying a mutation in the p75 gene (Figure 3e), we
hypothesized that SHP activity was enhanced by MAG
stimulation. We therefore examined the phosphorylation
states of Tyr-542 and Tyr-580 of SHP-2 in CGNs, as the
phosphorylation of these sites reﬂects the catalytic activity of
this protein.
8 Immunoblotting with phospho-Tyr-580-speciﬁc
antibodies revealed that MAG stimulation increased SHP-2
Tyr-580 phosphorylation in a time-dependent manner, with
maximal activation at 20min (Figure 3f). However, there was
no change in the SHP-2 phosphorylation level in CGNs from
mice carrying a mutation in the p75 gene (Figure 3g). SHP-2
phosphotyrosine phosphatase (PTP) activity was also deter-
mined directly by using ﬂuorogenic 6,8-diﬂuoro-4-methylum-
belliferyl phosphate (DiFMUP) as the substrate in a
phosphatase assay, and the relative SHP-2 PTP activity
was found to be increased by MAG stimulation in the WT
CGNs (Figure 3h, left). In contrast, we observed no enhance-
ment of SHP-2 activity as a result of MAG-Fc treatment in the
CGNs from mice bearing the p75 mutation (Figure 3h, right).
These results demonstrate that MAG binding to PIR-B
induces SHP-2 activation by a p75-dependent mechanism.
p75 inhibits axon regeneration in vivo. To assess the
relevance of our in vitro observations, we also examined
the involvement of p75 in axon growth inhibition in vivo with
the optic nerve crush injury model in 3-week-old mice.
Immunohistochemical analysis revealed that although p75
was expressed in the retina before injury (Figure 4a), there
was an increase in the level of p75 expression following optic
nerve injury (Figure 4b). The regeneration of optic nerve
axons was traced by injecting the cholera toxin beta subunit
(CTB) conjugated to Alexa Fluor 555 (Invitrogen, Carlsbad,
CA, USA) into the vitreous of the retina 12 days after the
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Figure 3 p75 is required for MAG-induced dephosphorylation of TrkB and SHP activation. (a) Western blots examining the level of TrkB tyrosine phosphorylation in
transfectedCOS-7cells.Thecellsweretransfectedwiththeindicatedconstructsandtreatedwith orwithoutMAG-Fc(25mg/ml)for30mininthepresenceof100ng/mlBDNF
for 5min. Anti-Trk antibodies were used to immunoprecipitate Trk, and the level of Trk phosphorylation was determined by western blotting with anti-phospho-Tyr antibodies.
(b–d)WesternblotsshowingthelevelofTrkBtyrosinephosphorylationin(b)dissociatedretinalneuronsfromWTandp75KOmice,(c)transfectedCOS-7cellsco-expressing
TrkBFL-HAandPIR-BFLincombinationwithp75FL-Mycorp75ECD-Myc,and(d)COS-7cellstransfectedwithorwithoutaconstructexpressingcatalyticallyinactiveSHP-2
(SHP-2 C459S). (e) Western blots showing the expression of the indicated proteins in WT and p75 KO CGNs. (f) Western blots for detecting the levels of phospho-SHP-2
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Cell Death and Diseasecrush injury (Figure 4c). It was found that the optic nerve
regeneration 14 days after injury was signiﬁcantly increased
in mice bearing the p75 mutation when compared with WT
mice, although the extent of regeneration was not high
(Figure 4d). The phosphorylation level of TrkB was also
found to be increased (Figure 4e, left), while that of SHP-2
was decreased (Figure 4e, right) in the extracts of the eye-
cups and optic nerves prepared from injured p75 knockout
(KO) mice. These results indicate that p75 contributes to
axon growth inhibition after optic nerve crush injury in mice.
Discussion
In this study, we show directly for the ﬁrst time that MAG
binding to PIR-B leads to enhancement of SHP activity
(Supplementary Figure S1). Intriguingly, p75 is required for
this action. SHP-2 belongs to a subfamily of non-transmem-
brane PTPs that contain 2 N-terminal SH2 domains (N-SH2
and C-SH2), a catalytic domain, and a C-terminal tail with two
tyrosyl phosphorylation sites (Tyr-542 and Tyr-580) and a
proline-rich motif. In the proposed basal state, SHP-2 is
inactive because the ‘backside loop’ of the N-SH2 domain is
associated with catalytic cleft and maintained in a closed
state. SHP-2 has been suggested to be activated by C-tail
tyrosyl phosphorylation, which may open the enzyme and
enable access to the activate site.
8,9 p75 may directly or
indirectly regulate these processes. It is also intriguing to
hypothesize that SHP regulation by p75 might be a relevant
mechanism opposing the function of p75 against Trk
receptors. The precise mechanism of the regulation of SHP
activity by p75 will be determined in future studies.
p75 is known to be required for the axon growth inhibition
mediated by NgR. Because we found that p75 also
participates in PIR-B signal transduction, it appears that p75
is involved in the signals mediated by both the receptors.
However, it should be noted that triple-knockout mice lacking
all three of the ligands for these receptors show no
enhancement in regeneration of the injured corticospinal tract
or in motor recovery after spinal cord injury.
10 Results
consistent with this were also observed in spinally injured
mice that carry a mutation in the p75 gene.
11,12 However, in
the optic nerve injury mouse model, we observed regenera-
tion, although not robust, was signiﬁcant. These seemingly
contradictory results might be explained by differences in the
p75 expression level in the corresponding tissues. In the optic
nerve, p75 is expressed (Figure 4a), whereas p75 expression
is weak or undetectable in corticospinal neurons.
11 Therefore,
p75 may have a role in inhibiting axon regeneration in speciﬁc
p75-expressing neurons in the CNS. MAG, Nogo, and OMgp
may act as axon growth inhibitors in a neuron-type-speciﬁc
manner; this issue should be assessed in other neuronal
tracts. It should also be noted that SHP inhibition promoted
axon regeneration of the injured optic nerves,
4 which is
consistent with the ﬁndings reported in this study.
We shouldalsoconsiderthe ﬁndingthatp75transducesthe
Sema3Asignal.
13BecauseSema3Aisoneoftheaxongrowth
inhibitors in the CNS,
14 the in vivo data obtained in p75-
deﬁcient mice might be the result of a lack of Sema3A signals
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Cell Death and Diseaseindependent of the three proteins. In addition, as TrkB activity
is upregulated in the retinal neurons from p75NTR KO mice
(Figure 4e), the myelin signal is attenuated and TrkB is
activated in the p75NTR KO neurons. In conclusion, the
present study clearly demonstrates that inhibition of p75
promotes axon regeneration in the CNS and supports the
positive role of p75 as an axon growth inhibitory receptor.
Materials and Methods
Animals. We purchased C57BL/6J mice (age, 8 weeks) from Charles River
Laboratories. These mice were bred and maintainedin the Institute of Experimental
Animal Sciences, Osaka University Graduate School of Medicine. We used a
C57BL/6J mouse strain bearing a targeted disruption of the third exon of the p75
gene. The mice were generated by electroporating the targeting vector into the J1
ES cell line derived from a male mouse strain129 embryo;
7 the strain was originally
obtained from Jackson Laboratory (Bar Harbor, ME, USA). All experimental
procedures were approved by the Institutional Committee of Osaka University.
Reagents and antibodies. The following reagents were used: puriﬁed
MAG-Fc (25mg/ml), recombinant rat Nogo A-Fc (200nM; R&D Systems,
Minneapolis, MN, USA), mouse OMgp (2mg/ml; R&D Systems), and BDNF
(100ng/ml;Peprotech,RockyHill,NJ,USA).StableCHOcelllinessecretinghuman
MAG-Fc were provided by Endo M (Kobe University). The cells were cultured in
serum-free medium. Conditioned medium was collected after 3 days, and MAG-Fc
was puriﬁed with protein A-Sepharose beads. The following antibodies were used:
monoclonal anti-HA (HA-7, H3663, 1:5000; Sigma-Aldrich, St Louis, MO, USA),
anti-c-Myc, (9E10, sc-40, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-SHP-2 (1:1000, BD Transduction Laboratories), biotinylated anti-TrkB
(1:2500; R&D systems), anti-alpha-Tubulin (1:1000; Santa Cruz Biotechnology),
and anti-neuronal class III b-tubulin (Tuj1, 1:5000; Covance Laboratories, Inc.,
Berkeley, CA, USA) antibodies. Polyclonal anti-HA (ab9110, 1:5000; Abcam,
Cambridge, UK), anti-p75 (G323A, 1:1000; Promega, Madison, WI, USA),
anti-SHP-1, anti-SHP-2, anti-Trk, anti-TrkB, (1:1000; Santa Cruz Biotechnology),
anti-PIR-B, (sc-9608 or sc-9609, 1:1000; Santa Cruz Biotechnology), anti-
phospho-SHP-2 (1:500; Cell Signaling Technology, Danvers, MA, USA), anti-PIR-
B (AF2754, 1mg/ml; R&D systems), and anti-PIR-A/B (550348, 1:1000; BD
Pharmingen, San Diego, CA, USA) antibodies. HRP-linked anti-mouse, anti-rabbit
andanti-ratIgGsecondaryantibodies(CellSignalingTechnology),HRP-linkedanti-
goat IgG secondary antibody (Santa Cruz Biotechnology), Streptavidin peroxidase
(Roche Applied Science, Indianapolis, IN, USA), and Alexa conjugated secondary
antibodies (Molecular Probes, Eugene, OR, USA) were used.
Plasmid constructs and siRNA. Amino-terminally HA- or Myc-tagged full-
length human p75 (NM_002507) were subcloned into the pcDNA3 vector
(Invitrogen, Carlsbad, CA, USA).
15 The extracellular or intracellular domains of
p75 were generated from p75-HA. Mouse PIR-B (NC_000073) was subcloned into
the pcDNA3.1Zeo(þ) vector as previously described.
16 Rat TrkB (NM_012731)
constructs were provided by Barde Y-A.
17 A mammalian expression vector
encoding human TrkA (NM_001012331, Addgene plasmid 15002)
18 and human
SHP-2 C459S (Addgene plasmid 8382) was obtained from Addgene (Cambridge,
MA, USA).
Rat TrkB lacking Y515 and/or Y705/706 were made by site-directed
mutagenesis.
Cell culture. COS-7 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen) containing 10% fetal bovine serum (FBS). Transient
transfection of COS-7 cells was performed using Lipofectamine 2000 according
to the manufacturer’s instructions (Invitrogen). The cells were lysed 24–48h after
the transfection and used for immunoprecipitation. Primary dissociated cultures of
CGNs from P7 mice were prepared as reported.
19 After 24h of plating the neurons
on poly-l-lysine-coated dishes, the medium was replaced with DMEM/F12
containing 0.1% BSA. Following 24h incubation, the neurons were harvested for
immunoprecipitation or western blotting. For dissociated retinal cell cultures, P7–P9
mice were used. Eyes were enucleated, and retinas were dissected and incubated
at 371C for 30min in a digestion solution containing papain (16.5U/ml; Worthington
Biochemical, Lakewood, NJ, USA), DNase (0.5mg/ml; Sigma-Aldrich), and
L-cysteine (0.3g/ml, Sigma) in phosphate-buffered solution (PBS). Cells were
then rinsed with DMEM containing 10% FBS and centrifuged at 1000r.p.m for
5min. To remove cell debris, the cell suspension was passed through a cell strainer
(70mm; BD Falcon, Franklin Lakes, NJ, USA). After centrifugation, the supernatant
was discarded and the cells were carefully resuspended in DMEM supplemented
with B27 (1:50; Invitrogen) or subjected to nucleofection.
Nucleofection. Retinal neurons were isolated as described above. The cells
were washed and resuspended in room temperature Mouse Neuron Nucleofector
Solution (Amaxa; Lonza Cologne AG, Cologne, Germany). The cell–nucleofector
solution complex (100ml) and the plasmids (3mg) were then gently mixed
and transferred into a cuvette, followed by nucleofection using the nucleofector
program O-05 (Lonza, Gaithersburg, MD, USA).
Co-immunoprecipitation. Cells were washed with ice-cold PBS and lysed
on ice in lysis buffer (50mM Tris-HCl (pH 7.4), 150mM NaCl, 0.5–1% NP-40,
10mM NaF, and 1mM Na3VO4) containing protease inhibitor cocktail (Roche
Diagnostics,Basel,Switzerland),followedbycentrifugationat41Cwith15000r.p.m.
for 10min. The supernatants were incubated with the indicated antibodies for 2h or
overnight at 41C. The immune complexes were collected for 1h at 41C with the
protein A, protein G-Sepharose (GE Healthcare, Chalfont St. Giles, England), or
streptavidin-agarose beads (Thermo Scientiﬁc, Waltham, MA, USA) precoated with
0.1–0.5% BSA. After washing the beads thrice with lysis buffer, the proteins were
eluted by boiling in 25mlo f2  sample buffer for 5min, and subjected to SDS-
PAGE, followed by western blotting. Where indicated, the cells were treated with
25mg/ml MAG-Fc or recombinant human IgG-Fc (R&D systems).
Western blotting. Cell lysates were boiled in sample buffer for 5min. The
proteins were separated on sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto polyvinylidene diﬂuoride
(PVDF) membranes (Millipore, Billerica, MA, USA). The membrane was blocked
with5%non-fatdrymilkinPBScontaining0.05%Tween-20(PBS-T)andincubated
for 1h at room temperature or overnight at 41C, with the primary antibody diluted in
PBS-T containing 1% non-fat dry milk. After washing in PBS-T, the membrane was
incubated with horseradish peroxidase-linked anti-mouse IgG antibody, anti-rabbit
IgG antibody (Cell Signaling Technology), or Streptavidin-POD (Roche Applied
Science). For detection, an ECL chemiluminescence system (GE Healthcare) was
used. Signals were detected and quantiﬁed using the LAS-3000 image analyzer
(Fuji Film, Tokyo, Japan).
PTP activity assay. A PTP activity assay was performed as previously
described.
20 CGNs were pre-treated with or without MAG-Fc. Cells were lysed in
ice-coldPTP lysis buffer (25mM HEPES,pH 7.4; 150mM NaCl; 2mM EDTA; 0.5%
Triton X-100) containing a protease inhibitor cocktail. The lysates were incubated
with anti-SHP-2 antibody and protein A-Sepharose for 2h at 41C. The SHP-2
immune complexes were washed three times with PTP lysis buffer and twice with
reaction buffer (20mM HEPES, pH 7.4; 1mM EDTA; 5% glycerol; and 1mM
dithiothreitol). The immunoprecipitates were resuspended in 100ml of reaction
buffer containing 50mM DiFMUP (Invitrogen) and incubated at room temperature
for 20min. The supernatants were transferred to 96-well plates, and the DiFMUP
ﬂuorescence signal was measured at an excitation wavelength of 355nm and an
emission wavelength of 460nm with a plate reader (Softmax; Molecular Devices,
Sunnyvale, CA, USA).
RNA extraction, reverse transcription, and real-time PCR. Total
RNAwas extractedfromretinae byTrizol (Invitrogen)andreversetranscribedusing
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
CA, USA). The expression of mRNA was examined by real-time PCR using a 7300
FastReal-TimePCR system(AppliedBiosystems).SYBRGreenassayswereused
to quantitate p75. Primers for RGM. and neogenin were designed as previously
described.
21 The speciﬁcity of each primer set was determined with a pre-test
showing the speciﬁc ampliﬁcation for a speciﬁc gene by gel visualization and
sequencing. A sample volume of 20ml was used for SYBR green assays, which
contained a 1x ﬁnal concentration of Power SYBR green PCR master mix (Applied
Biosystems), 400nM gene-speciﬁc primers, and 1ml template. The PCR cycles
started with an UNG digestion stage at 501C for 2min, and an initial denaturation
period at 951C lasting for 10min, followed by 40 cycles at 951C for 15s,
an annealing phase conducted at 601C for 1min, and a gradual increase in
temperature from 60 to 951C during the dissociation stage.
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of Gapdh mRNA in each sample. The results of cycle threshold values (Ct values)
were calculated by the DDCt method to obtain the fold differences.
Immunohistochemistry. Cryostat sections were incubated with blocking
solution containing 5% BSA and 0.1% Triton X-100 in PBS for 1h at room
temperature, followed by overnight incubation with the primary antibodies at 41C.
Immunoreactivity was visualized using ﬂuorescence-conjugated secondary
antibodies. Coverslips were then mounted with mounting medium.
Optic nerve injury and anterograde labeling. Optic nerve injury was
performed as previously described.
22 Brieﬂy, the left optic nerves of P21 mice were
exposed intraorbitally and crushed with ﬁne forceps. On day 12 after axotomy, 2mg
of Alexa555-conjugated CTB (Invitrogen) was injected into the vitreous body with a
glass needle. On day 14 after axotomy, the animals were perfused with 4%
paraformaldehyde (PFA) and the lens and vitreous body were removed. The
remaining eye-cup, which contained the nerve segment, was post-ﬁxed and
immersed in10–30%sucroseovernightat41C.Theeye-cupswerethenembedded
in OCT compound (Tissue Tek; Sakura Finetek, Torrance, CA, USA). Tissues were
frozen in dry ice, and 16-mm serial cross-sections were prepared using a cryostat
and collected on MAS-coated glass slides (Matsunami Glass, Osaka, Japan).
Quantiﬁcation of axonal regeneration. Axonal regeneration was
quantiﬁed by counting the number of CTB-labeled axons extending 0.2, 0.5, and
1.0mm from the end of the crush site in four different sections. The cross-sectional
width of the nerve was measured at the point where the counts were taken, and
used to calculate the number of axons per millimeter of nerve width. This number
was then averaged over the ﬁve sections. The total number of axons extending the
distance d in a nerve with a radius r (
P
ad) was estimated by summing the number
in all the sections with a thickness t (16mm), using the following formula:
Sad ¼ pr2 ðaverageaxons=mmÞ=t
Statistical analysis. The data are presented as the mean±S.E.M. of at least
three independent experiments. Statistical analyses were performed using Welch’s
t-test (Figure 3h), two-way ANOVA followed by post-hoc Bonferroni analysis
(Figures 4b and d). P values of less than 0.05 were considered signiﬁcant.
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